GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
21 Feb 2017 05:14 PM
RNS
Director/PDMR Shareholding
20 Feb 2017 03:55 PM
RNS
Director/PDMR Shareholding
20 Feb 2017 02:12 PM
RNS
Director/PDMR Shareholding
17 Feb 2017 03:58 PM
RNS
Director/PDMR Shareholding
17 Feb 2017 03:57 PM
RNS
Director/PDMR Shareholding
17 Feb 2017 03:55 PM
RNS
Director/PDMR Shareholding
15 Feb 2017 05:15 PM
RNS
Director/PDMR Shareholding
14 Feb 2017 12:43 PM
RNS
Director/PDMR Shareholding
14 Feb 2017 09:49 AM
RNS
Director/PDMR Shareholding
14 Feb 2017 07:00 AM
RNS
ViiV Phase III results Dolutegravir & Rilpivirine
13 Feb 2017 05:04 PM
RNS
Director/PDMR Shareholding
10 Feb 2017 03:47 PM
RNS
Director/PDMR Shareholding
10 Feb 2017 11:10 AM
RNS
Director/PDMR Shareholding
10 Feb 2017 08:42 AM
RNS
Blocklisting Application
09 Feb 2017 05:32 PM
RNS
Director/PDMR Shareholding
09 Feb 2017 01:42 PM
RNS
Director/PDMR Shareholding
08 Feb 2017 05:27 PM
RNS
Director/PDMR Shareholding
08 Feb 2017 12:00 PM
RNS
Final Results
01 Feb 2017 11:02 AM
RNS
Total Voting Rights
25 Jan 2017 04:17 PM
RNS
Director/PDMR Shareholding
24 Jan 2017 04:51 PM
RNS
Director/PDMR Shareholding
23 Jan 2017 03:45 PM
RNS
Director/PDMR Shareholding
20 Jan 2017 03:07 PM
RNS
Director/PDMR Shareholding
19 Jan 2017 07:05 AM
RNS
Corporate executive team changes
19 Jan 2017 07:00 AM
RNS
Corporate executive team changes
16 Jan 2017 06:25 PM
RNS
Director/PDMR Shareholding
16 Jan 2017 06:08 PM
RNS
Director/PDMR Shareholding
16 Jan 2017 05:15 PM
RNS
Director/PDMR Shareholding
16 Jan 2017 05:04 PM
RNS
Director/PDMR Shareholding
16 Jan 2017 04:54 PM
RNS
Director/PDMR Shareholding
16 Jan 2017 04:01 PM
RNS
Director/PDMR Shareholding
16 Jan 2017 03:51 PM
RNS
Director/PDMR Shareholding
13 Jan 2017 04:40 PM
RNS
Director/PDMR Shareholding
13 Jan 2017 03:44 PM
RNS
Director/PDMR Shareholding
13 Jan 2017 02:29 PM
RNS
Director/PDMR Shareholding
12 Jan 2017 04:38 PM
RNS
Director/PDMR Shareholding
10 Jan 2017 04:51 PM
RNS
Director/PDMR Shareholding
03 Jan 2017 10:34 AM
RNS
Total Voting Rights
20 Dec 2016 02:03 PM
RNS
ViiV starts HIV prevention study with cabotegravir
20 Dec 2016 07:17 AM
RNS
Blocklisting Application
20 Dec 2016 07:00 AM
RNS
ViiV announce phase III results for 2-drug regimen
19 Dec 2016 03:19 PM
RNS
Directorate Change
19 Dec 2016 09:32 AM
RNS
Phase III study start for closed triple in asthma
16 Dec 2016 05:32 PM
RNS
Treasury Stock
16 Dec 2016 10:45 AM
RNS
Director/PDMR Shareholding
13 Dec 2016 09:11 AM
RNS
Audit Tender Conclusion
12 Dec 2016 03:56 PM
RNS
Director/PDMR Shareholding
02 Dec 2016 03:49 PM
RNS
Director/PDMR Shareholding
02 Dec 2016 02:19 PM
RNS
GSK files closed triple therapy for COPD in EU
02 Dec 2016 07:01 AM
RNS
Relvar Ellipta approved in Japan for COPD

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

UK 100

Latest directors dealings